Direxion Daily Energy Bull 2X Shares ETF
ERX
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
VanEck Oil Services ETF
OIH
4
iShares US Telecommunications ETF
IYZ
5
Direxion Daily Financial Bear 3X Shares ETF
FAZ
US Stock MarketDetailed Quotes
GT Biopharma (GTBP)
- 0.4426
- -0.0074-1.64%
Trading Feb 24 14:42 ET
11.80MMarket Cap-0.13P/E (TTM)
0.4500High0.4300Low315.45KVolume0.4304Open0.4500Prev Close136.86KTurnover1.22%Turnover RatioLossP/E (Static)26.65MShares3.850052wk High3.92P/B11.43MFloat Cap0.401152wk Low--Dividend TTM25.82MShs Float591.9900Historical High--Div Yield TTM4.44%Range %0.4011Historical Low0.4330Avg Price1Lot Size
GTBP Stock Chart
Real-Time
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
GTBP Orderflow
Unit: --
GTBP Orderflow Trend
IntradayDayWeekMonth
No Data
GT Biopharma (GTBP) News
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GT Biopharma Announces FDA Clearance for GTB-5550 Phase 1 Clinical Trial Targeting Solid Tumors Expressing B7-H3
Express News | GT Biopharma Announces FDA Clearance of Investigational New Drug (Ind) Application for Gtb-5550 Trike®, a B7-H3-Targeted Natural Killer (Nk) Cell Engager for Solid Tumors Expressing B7-H3
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
GT Biopharma (GTBP) Stock Forum
$GT Biopharma (GTBP.US)$ anyone know if this company cured cancer yet? need it to take off been holding
1
$GT Biopharma (GTBP.US)$ What types of cancer will the Phase 1 trial focus on?
The trial will prioritize patients with advanced prostate, ovarian, and pancreatic cancers that have failed standard therapies.
How does GTB-5550 work?
GTB-5550 uses a TriKE platform to enhance the cancer-killing abilities of natural killer cells targeting the B7-H3 antigen on tumors.
What is the expected cash runway for GT Biopharma?
The company anticipates an unaudited pro forma cash balance of approximately $9 ...
The trial will prioritize patients with advanced prostate, ovarian, and pancreatic cancers that have failed standard therapies.
How does GTB-5550 work?
GTB-5550 uses a TriKE platform to enhance the cancer-killing abilities of natural killer cells targeting the B7-H3 antigen on tumors.
What is the expected cash runway for GT Biopharma?
The company anticipates an unaudited pro forma cash balance of approximately $9 ...
$GT Biopharma (GTBP.US)$ Reuters
2m
GT Biopharma Announces FDA Clearance of Investigational New Drug (Ind) Application for Gtb-5550 Trike®, a B7-H3-Targeted Natural Killer (Nk) Cell Engager for Solid Tumors Expressing B7-H3
2m
GT Biopharma Announces FDA Clearance of Investigational New Drug (Ind) Application for Gtb-5550 Trike®, a B7-H3-Targeted Natural Killer (Nk) Cell Engager for Solid Tumors Expressing B7-H3
2
4
$GT Biopharma (GTBP.US)$ solid news
Today, 8:06 AM : GT Biopharma shares rise after the company announces it submitted an IND to the FDA for its GTB-5550 TriKE solid tumor therapy and outlined plans for a 2026 Phase 1 basket trial.
For real time alerts join using the below link
Link: Join the Assassin Stocks Guild Discord Server!
Today, 8:06 AM : GT Biopharma shares rise after the company announces it submitted an IND to the FDA for its GTB-5550 TriKE solid tumor therapy and outlined plans for a 2026 Phase 1 basket trial.
For real time alerts join using the below link
Link: Join the Assassin Stocks Guild Discord Server!
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)